Johnson & Johnson 2Q Revenues: $16.5 billion (+9%) 2Q Earnings: $3.3 billion (+8%) YTD Revenues: $32.6 billion (+8%) YTD Earnings: $6.9 billion (+23%) Comments: Pharmaceutical sales were $6.3 billion (+3%), driven by Topamax sales ($677 million up 17%), Velcade sales ($205 million up 63%), Risperdal Consta sales ($343 million up 23%), and Remicade sales ($886 million up 2%). Growth was negatively impacted by lower sales of anemia drug Procrit, down 14% to $652 million, due to a dec...